|
18 Sep 2025 |
Zydus Lifesciences
|
Consensus Share Price Target
|
1044.90 |
1011.50 |
- |
-3.20 |
hold
|
|
|
|
|
14 Nov 2022
|
Zydus Lifesciences
|
ICICI Securities Limited
|
1044.90
|
448.00
|
423.80
(146.55%)
|
Target met |
Hold
|
|
|
Zydus Lifesciences (Zydus) reported Q2FY23 performance is broadly in line with our estimates. Revenue grew 7.3% YoY to Rs40.0bn (I-Sec: Rs40.0bn) on the back of India and US markets.
|
|
12 Nov 2022
|
Zydus Lifesciences
|
Motilal Oswal
|
1044.90
|
410.00
|
423.80
(146.55%)
|
Target met |
Neutral
|
|
|
|
|
13 Aug 2022
|
Zydus Lifesciences
|
ICICI Direct
|
1044.90
|
405.00
|
386.85
(170.10%)
|
Target met |
Hold
|
|
|
|
|
11 Aug 2022
|
Zydus Lifesciences
|
Prabhudas Lilladhar
|
1044.90
|
425.00
|
386.85
(170.10%)
|
Target met |
Buy
|
|
|
|
|
11 Aug 2022
|
Zydus Lifesciences
|
ICICI Securities Limited
|
1044.90
|
411.00
|
364.55
(186.63%)
|
Target met |
Accumulate
|
|
|
Zydus Lifesciences (Zydus) reported tepid operational performance in Q1FY23.
|
|
31 May 2022
|
Zydus Lifesciences
|
Geojit BNP Paribas
|
1044.90
|
440.00
|
363.20
(187.69%)
|
Target met |
Buy
|
|
|
|
|
23 May 2022
|
Zydus Lifesciences
|
Prabhudas Lilladhar
|
1044.90
|
450.00
|
373.40
(179.83%)
|
Target met |
Buy
|
|
|
|
|
09 Feb 2022
|
Zydus Lifesciences
|
Geojit BNP Paribas
|
1044.90
|
465.00
|
392.35
(166.32%)
|
|
Buy
|
|
|
Cadila Healthcare is India's leading vertically integrated pharmaceutical company. With its presence across the value chain, it manufactures finished dosage forms, active pharmaceutical ingredients, animal healthcare...
|
|
04 Feb 2022
|
Zydus Lifesciences
|
ICICI Securities Limited
|
1044.90
|
475.00
|
409.25
(155.32%)
|
|
Hold
|
|
|
In the last two years, KNL has increased its total paint manufacturing capacity by 28% to 5.3 lakh tonnes at an investment of ~| 1100 crore Q3FY22 Results: Lower industrial volume offtake and delay in passing of higher...
|
|
04 Feb 2022
|
Zydus Lifesciences
|
Motilal Oswal
|
1044.90
|
490.00
|
409.25
(155.32%)
|
|
Buy
|
|
|
Cadila Healthcare (CDH) delivered lower-than-expected 3QFY22 earnings, weighed by lower Domestic Formulation (DF) / US / EM sales and increased operational costs. CDH continues its effort to build the product pipeline and niche launches (including g-Revlimid) for the US market. Even innovation-led products are advancing well in the respective clinical stages of development. We cut our EPS estimates by 2%/4%/4% for FY22E/FY23E/FY24E and reduce PE multiple to 21x (from 25x earlier) to factor in a) moderate growth in the US business over the medium term and b) the weaker outlook on the...
|